New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out
Loading...
Shape
Pasithea Therapeutics Corp.
KTTA
Shape
US Flag

NASDAQ

Unprofitable

Unprofitable

4M

Biotechnology

Next Earning date - 11 Nov 2024

4M

Biotechnology

Next Earning date - 11 Nov 2024

3.96USD
Shape-0.08 ( -1.98%)
Market Open
favorite-chart

Relative Strenght

18
favorite-chart

Volume Buzz

-100%
favorite-chart

Earning Acce

No
favorite-chart

Dist 52w H.

77%
OverviewChart

Quote Panel

Shape
Updated October 25, 2024
1W -9.79 % 1M -32.31 % 3M -21.58 % 1Y -45.30 %

Key Metrics

Shape

  • Market Cap

    4.13M

  • Shares Outstanding

    1.04M

  • Share in Float

    802456

  • Dividende

    0

  • Earning Date

    11 Nov 2024

  • Price Target

    3.96

  • Average Volume

    934770

  • Beta

    0.77

  • Range

    3.61-17.4

  • Industry

    Biotechnology

  • Website

    https://www.pasithea.com

  • Sector

    Healthcare

Fundamentals

Shape

N/A

P/E Ratio

4.23x

P/S Ratio

0.26x

P/B Ratio

0.0

Debt/Equity

-1678.6%

Net Margin

$-14.8

EPS

How KTTA compares to sector?

P/E Ratio

KTTA

0x

NTRBW -9x
ZIVO -4x
MNOV -10x
ELYM -2x
VRAX -1x

Relative Strength

Shape

KTTA

Sector

loading...

Top 5 RS in Group

Symbol

Company

RS

5-Day Perf.

Forecast

Shape

No Data Available

Analyst rating

No Data Available

Last analyst upgrade/downgrade

No Data Available

Earnings GrowthShape

status-upYoY

Current

Estimates

Q2.22

arrow
arrow

N/A

-0.08
vs -0.07

Q3.22

arrow
arrow

N/A

-0.20
vs -0.17

Q4.22

arrow
arrow

N/A

-0.15
vs 0.06

Q1.23

arrow
arrow

N/A

-10.55
vs -0.07

Q2.23

arrow
arrow

N/A

-0.14
vs -0.08

Q3.23

arrow
arrow

N/A

-0.14
vs -0.20

Q4.23

arrow
arrow

N/A

-4.85
vs -0.15

Q1.24

arrow
arrow

N/A

-3.70
vs -10.55

Q2.24

arrow
arrow

N/A

-3.71
vs -0.14

Q3.24

arrow
arrow

+1201%

1.54
vs -0.14

Sales GrowthShape

status-upYoY

Current

Estimates

Q1.22

arrow
arrow

NA

13.7K  vs NA

Q2.22

arrow
arrow

NA

13.6K  vs NA

Q3.22

arrow
arrow

NA

218.6K  vs NA

Q4.22

arrow
arrow

+1498%

240.7K  vs 15.1K

Q1.23

arrow
arrow

-100%

NA  vs 13.7K

Q2.23

arrow
arrow

-100%

NA  vs 13.6K

Q3.23

arrow
arrow

-100%

NA  vs 218.6K

Q4.23

arrow
arrow

+306%

976.3K  vs 240.7K

Q1.24

arrow
arrow

NA

NA  vs NA

Q2.24

arrow
arrow

NA

NA  vs NA

Return on EquityShape

status-upQoQ

Q3.22

arrow
arrow

-10%

-0.10
vs -0.04

Q4.22

arrow
arrow

-9%

-0.09
vs -0.10

Q1.23

arrow
arrow

-703%

-7.03
vs -0.09

Q2.23

arrow
arrow

-11%

-0.11
vs -7.03

Q3.23

arrow
arrow

-13%

-0.13
vs -0.11

Q4.23

arrow
arrow

-22%

-0.22
vs -0.13

Q1.24

arrow
arrow

-19%

-0.19
vs -0.22

Q2.24

arrow
arrow

-24%

-0.24
vs -0.19

Institutionnal OwnershipShape

status-upQoQ

Q1.22

arrow
arrow

7

7
vs 6

17%

Q2.22

arrow
arrow

8

8
vs 7

14%

Q3.22

arrow
arrow

8

8
vs 8

NA

Q4.22

arrow
arrow

11

11
vs 8

38%

Q1.23

arrow
arrow

12

12
vs 11

9%

Q2.23

arrow
arrow

12

12
vs 12

NA

Q3.23

arrow
arrow

12

12
vs 12

NA

Q4.23

arrow
arrow

8

8
vs 12

-33%

Earnings Growth

Latest News

KTTA

globenewswire.com

7 hours ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer
KTTA

benzinga.com

8 hours ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?
KTTA

globenewswire.com

8 hours ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies
KTTA

globenewswire.com

8 hours ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board
KTTA

globenewswire.com

9 hours ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
KTTA

globenewswire.com

18 hours ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

New Feature Coming Soon, Stay Tuned!

ShapeShape